Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 4 | EJNMMI Radiopharmacy and Chemistry

Fig. 4

From: A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals

Fig. 4

Schematic of the distribution of radiolabeled compounds, unbound metal (transformed into the EDTA complex upon exposure to the mobile phase), and daughter nuclei ejected from the labeled compounds following radioactive decay during the TLC running period. The DOTA-containing ligands are expected to chelate 209/213Bi and 209Pb in solution at 95 °C, but not to chelate daughter products generated by radioactive decay

Back to article page